title: High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.
abstract: We analysed the treatment outcome of primary refractory HD patients managed with high-dose chemotherapy and haematopoietic cell transplantation. Data of 65 adult patients who underwent HDC/ASCT in nine Polish centres for primary resistant Hodgkin's disease between June 1991 and July 2000 were collected retrospectively. Response rate to HDC/ASC: CR, 54%; PR, 20%; less than PR, 15%; early deaths, 11%. Actuarial 3-year OS and PFS were 55% and 36%, respectively. In multivariate analysis, lack of bulky lymph nodes and use of immunotherapy were favourable factors for both OS and PFS. IPF <3 at the time of transplantation was predictive for PFS. However, the prognostic impact of immunotherapy should be interpreted with caution since this group included more patients who achieved CR after HDC/ASCT. The results of HDC/ASCT are encouraging and confirm earlier findings. The role of immunotherapy should be further investigated in prospective trials.
authors.affiliation: Department of Haematology, Medical University, Gdańsk, ul. Debinki, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Czyz
authors.forename: A
authors.initials: A
authors.lastname: Hellmann
authors.forename: R
authors.initials: R
authors.lastname: Dziadziuszko
authors.forename: J
authors.initials: J
authors.lastname: Hansz
authors.forename: J
authors.initials: J
authors.lastname: Goździk
authors.forename: J
authors.initials: J
authors.lastname: Hołowiecki
authors.forename: B
authors.initials: B
authors.lastname: Stella-Hołowiecka
authors.forename: Ł
authors.initials: Ł
authors.lastname: Kachel
authors.forename: W
authors.initials: W
authors.lastname: Knopińska-Posłuszny
authors.forename: A
authors.initials: A
authors.lastname: Nagler
authors.forename: J
authors.initials: J
authors.lastname: Meder
authors.forename: J
authors.initials: J
authors.lastname: Walewski
authors.forename: E
authors.initials: E
authors.lastname: Lampka
authors.forename: K
authors.initials: K
authors.lastname: Sułek
authors.forename: W
authors.initials: W
authors.lastname: Sawicki
authors.forename: A
authors.initials: A
authors.lastname: Lange
authors.forename: K
authors.initials: K
authors.lastname: Forgacz
authors.forename: K
authors.initials: K
authors.lastname: Suchnicki
authors.forename: T
authors.initials: T
authors.lastname: Pacuszko
authors.forename: A
authors.initials: A
authors.lastname: Skotnicki
authors.forename: P
authors.initials: P
authors.lastname: Mensah
authors.forename: W
authors.initials: W
authors.lastname: Jurczak
authors.forename: K
authors.initials: K
authors.lastname: Kuliczkowski
authors.forename: T
authors.initials: T
authors.lastname: Wróbel
authors.forename: G
authors.initials: G
authors.lastname: Mazur
authors.forename: A
authors.initials: A
authors.lastname: Dmoszyńska
authors.forename: M
authors.initials: M
authors.lastname: Wach
authors.forename: T
authors.initials: T
authors.lastname: Robak
authors.forename: K
authors.initials: K
authors.lastname: Warzocha
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality*; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D015996:Survival Rate; D014182:Transplantation, Autologous / Q000401:mortality; D016896:Treatment Outcome